Anzeige
Mehr »
Donnerstag, 04.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E5QA | ISIN: XS2337703537 | Ticker-Symbol:
Frankfurt
04.09.25 | 13:04
100,01 
-0,01 % -0,01
Branche
Pharma
Aktienmarkt
Anleihen
1-Jahres-Chart
GRUENENTHAL GMBH Chart 1 Jahr
5-Tage-Chart
GRUENENTHAL GMBH 5-Tage-Chart
RealtimeGeldBriefZeit
100,01100,9215:17
100,09100,7215:18
PR Newswire
185 Leser
Artikel bewerten:
(1)

Grünenthal Group: Grünenthal PRO is joining SHL Medical's alliance partnership network to offer final assembly service for Molly autoinjectors

AACHEN, Germany, Sept. 4, 2025 /PRNewswire/ -- Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems. Through this collaboration, Grünenthal PRO will offer final assembly, packaging and labelling of Molly® autoinjector.

Grünenthal PRO will expand its capacity for final assembly of SHL autoinjectors by installing additional assembly lines in its Origgio, Italy facility in 2026. These new pre-validated lines for Molly® 1.0 and 2.25 mL autoinjector platform will enhance speed-to-market for pharma and biotech companies, building on Grünenthal's 10 year-experience in SHL autoinjector assembly services.

In parallel, SHL customers will benefit from access to Grünenthal PRO's established expertise and capacity in delivering high quality, reliable contract manufacturing services.

"Speed-to-market is a decisive advantage in today's biopharma landscape," says Victor Barbosa, Executive Vice President of Global Operations at Grünenthal. "With our deep expertise in autoinjector final assembly and the new high-speed line launching in 2026, Grünenthal is uniquely positioned to deliver agile, large-scale solutions. Our collaboration with SHL enhances this capability, reinforcing our role as a trusted CDMO partner for injectable therapies worldwide."

Molly® is a single-dose autoinjector built on modular platform technology that helps pharma and biotech companies reduce initial investments and accelerate timelines. Molly® boasts an unparalleled track record in combination product approvals and is designed to meet the evolving requirements of future autoinjectors.

Markus Puusepp, SHL Medical's Chief Growth Officer, commented on the collaboration: "This new partnership builds on several years of successful project collaboration between SHL Medical and Grünenthal PRO for joint customers. We're excited to deepen our collaboration by officially welcoming Grünenthal PRO as a strategic partner, further strengthening our trusted relationship."

The new Molly® autoinjector assembly line to be installed by Grünenthal PRO will be procured from SHL Advantec, a sub-group of SHL Medical and global provider of high-performance, fully integrated precision tooling and advanced automation solutions for the healthcare sector and other industries.

About SHL Medical
As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose - Enabling Patients' Independence - SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems.

Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth.

For additional information, visit http://www.shl-medical.com/

About Grünenthal PRO
Grünenthal PRO is the contract manufacturing division of Grünenthal, offering end-to-end services in pharmaceutical assembly, packaging, and labelling. With a strong focus on injectable therapies and advanced automation, Grünenthal PRO supports global pharma and biotech companies in accelerating time-to-market and ensuring high-quality delivery. For more information, visit www.grunenthal-pro.com.

For additional information, visit www.grunenthal-pro.com

SHL
Media contact
Christine Mueller
Corporate Communications
info@shl-medical.com
+41 41 368 00 00

Grünenthal PRO
Media contact
Grünenthal PRO Communications
info@grunenthal-pro.com
+49 (0)241 569-0
https://www.grunenthal-pro.com/contact-us

Cision View original content:https://www.prnewswire.co.uk/news-releases/grunenthal-pro-is-joining-shl-medicals-alliance-partnership-network-to-offer-final-assembly-service-for-molly-autoinjectors-302545524.html

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.